(616 Kb) ❲Limited MANUAL❳

: Both groups had roughly the same time (about 85–87 months) from their initial diagnosis until they started ibrutinib treatment. Clinical Implications

: Despite the high rate of stopping, the overall survival and progression-free survival (estimated at 35 months) remained excellent. Real-World vs. Clinical Trials (616 KB)

: Patients in clinical trials were generally younger, with a mean age of 58 compared to 61 in this real-world group. : Both groups had roughly the same time

Toxicities and outcomes of 616 ibrutinib-treated patients in ... - PMC Clinical Trials : Patients in clinical trials were

Provide a breakdown of the used by the researchers in this study. Which of these would be most helpful for you?

This article, available through PubMed Central (PMC) , provides a comprehensive look at how the drug performs in real-world clinical settings compared to controlled trials. Study Overview: The 616-Patient Cohort

The researchers analyzed a large group of 616 patients with who were treated with ibrutinib. The goal was to see if the high success rates found in clinical trials were mirrored in everyday medical practice across various hospitals. Key Findings and Statistics